Global NMDA Receptor Antagonist Market Growth 2022-2028
The global market for NMDA Receptor Antagonist is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC NMDA Receptor Antagonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States NMDA Receptor Antagonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe NMDA Receptor Antagonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China NMDA Receptor Antagonist market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key NMDA Receptor Antagonist players cover Algernon Pharmaceuticals, Relmada Therapeutics, UCB, Avanir Pharmaceuticals and Axsome Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global NMDA Receptor Antagonist market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global NMDA Receptor Antagonist market, with both quantitative and qualitative data, to help readers understand how the NMDA Receptor Antagonist market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the NMDA Receptor Antagonist market and forecasts the market size by Type (Vaccine and Monoclonal Antibody,), by Application (Parkinson's Disease, Alzheimer's Disease and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Vaccine
Monoclonal Antibody
Segmentation by application
Parkinson's Disease
Alzheimer's Disease
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Algernon Pharmaceuticals
Relmada Therapeutics
UCB
Avanir Pharmaceuticals
Axsome Therapeutics
Seelos Therapeutics
PharmaTher
Cessatech
ATAI Life Sciences
Small Pharma
Bexson Biomedical
DemeRx
Chapter Introduction
Chapter 1: Scope of NMDA Receptor Antagonist, Research Methodology, etc.
Chapter 2: Executive Summary, global NMDA Receptor Antagonist market size (sales and revenue) and CAGR, NMDA Receptor Antagonist market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: NMDA Receptor Antagonist sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global NMDA Receptor Antagonist sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global NMDA Receptor Antagonist market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Algernon Pharmaceuticals, Relmada Therapeutics, UCB, Avanir Pharmaceuticals, Axsome Therapeutics, Seelos Therapeutics, PharmaTher, Cessatech and ATAI Life Sciences, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global NMDA Receptor Antagonist Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for NMDA Receptor Antagonist by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for NMDA Receptor Antagonist by Country/Region, 2017, 2022 & 2028
2.2 NMDA Receptor Antagonist Segment by Type
2.2.1 Vaccine
2.2.2 Monoclonal Antibody
2.3 NMDA Receptor Antagonist Sales by Type
2.3.1 Global NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
2.3.2 Global NMDA Receptor Antagonist Revenue and Market Share by Type (2017-2022)
2.3.3 Global NMDA Receptor Antagonist Sale Price by Type (2017-2022)
2.4 NMDA Receptor Antagonist Segment by Application
2.4.1 Parkinson's Disease
2.4.2 Alzheimer's Disease
2.4.3 Others
2.5 NMDA Receptor Antagonist Sales by Application
2.5.1 Global NMDA Receptor Antagonist Sale Market Share by Application (2017-2022)
2.5.2 Global NMDA Receptor Antagonist Revenue and Market Share by Application (2017-2022)
2.5.3 Global NMDA Receptor Antagonist Sale Price by Application (2017-2022)
3 Global NMDA Receptor Antagonist by Company
3.1 Global NMDA Receptor Antagonist Breakdown Data by Company
3.1.1 Global NMDA Receptor Antagonist Annual Sales by Company (2020-2022)
3.1.2 Global NMDA Receptor Antagonist Sales Market Share by Company (2020-2022)
3.2 Global NMDA Receptor Antagonist Annual Revenue by Company (2020-2022)
3.2.1 Global NMDA Receptor Antagonist Revenue by Company (2020-2022)
3.2.2 Global NMDA Receptor Antagonist Revenue Market Share by Company (2020-2022)
3.3 Global NMDA Receptor Antagonist Sale Price by Company
3.4 Key Manufacturers NMDA Receptor Antagonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NMDA Receptor Antagonist Product Location Distribution
3.4.2 Players NMDA Receptor Antagonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for NMDA Receptor Antagonist by Geographic Region
4.1 World Historic NMDA Receptor Antagonist Market Size by Geographic Region (2017-2022)
4.1.1 Global NMDA Receptor Antagonist Annual Sales by Geographic Region (2017-2022)
4.1.2 Global NMDA Receptor Antagonist Annual Revenue by Geographic Region
4.2 World Historic NMDA Receptor Antagonist Market Size by Country/Region (2017-2022)
4.2.1 Global NMDA Receptor Antagonist Annual Sales by Country/Region (2017-2022)
4.2.2 Global NMDA Receptor Antagonist Annual Revenue by Country/Region
4.3 Americas NMDA Receptor Antagonist Sales Growth
4.4 APAC NMDA Receptor Antagonist Sales Growth
4.5 Europe NMDA Receptor Antagonist Sales Growth
4.6 Middle East & Africa NMDA Receptor Antagonist Sales Growth
5 Americas
5.1 Americas NMDA Receptor Antagonist Sales by Country
5.1.1 Americas NMDA Receptor Antagonist Sales by Country (2017-2022)
5.1.2 Americas NMDA Receptor Antagonist Revenue by Country (2017-2022)
5.2 Americas NMDA Receptor Antagonist Sales by Type
5.3 Americas NMDA Receptor Antagonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NMDA Receptor Antagonist Sales by Region
6.1.1 APAC NMDA Receptor Antagonist Sales by Region (2017-2022)
6.1.2 APAC NMDA Receptor Antagonist Revenue by Region (2017-2022)
6.2 APAC NMDA Receptor Antagonist Sales by Type
6.3 APAC NMDA Receptor Antagonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe NMDA Receptor Antagonist by Country
7.1.1 Europe NMDA Receptor Antagonist Sales by Country (2017-2022)
7.1.2 Europe NMDA Receptor Antagonist Revenue by Country (2017-2022)
7.2 Europe NMDA Receptor Antagonist Sales by Type
7.3 Europe NMDA Receptor Antagonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa NMDA Receptor Antagonist by Country
8.1.1 Middle East & Africa NMDA Receptor Antagonist Sales by Country (2017-2022)
8.1.2 Middle East & Africa NMDA Receptor Antagonist Revenue by Country (2017-2022)
8.2 Middle East & Africa NMDA Receptor Antagonist Sales by Type
8.3 Middle East & Africa NMDA Receptor Antagonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NMDA Receptor Antagonist
10.3 Manufacturing Process Analysis of NMDA Receptor Antagonist
10.4 Industry Chain Structure of NMDA Receptor Antagonist
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NMDA Receptor Antagonist Distributors
11.3 NMDA Receptor Antagonist Customer
12 World Forecast Review for NMDA Receptor Antagonist by Geographic Region
12.1 Global NMDA Receptor Antagonist Market Size Forecast by Region
12.1.1 Global NMDA Receptor Antagonist Forecast by Region (2023-2028)
12.1.2 Global NMDA Receptor Antagonist Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global NMDA Receptor Antagonist Forecast by Type
12.7 Global NMDA Receptor Antagonist Forecast by Application
13 Key Players Analysis
13.1 Algernon Pharmaceuticals
13.1.1 Algernon Pharmaceuticals Company Information
13.1.2 Algernon Pharmaceuticals NMDA Receptor Antagonist Product Offered
13.1.3 Algernon Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Algernon Pharmaceuticals Main Business Overview
13.1.5 Algernon Pharmaceuticals Latest Developments
13.2 Relmada Therapeutics
13.2.1 Relmada Therapeutics Company Information
13.2.2 Relmada Therapeutics NMDA Receptor Antagonist Product Offered
13.2.3 Relmada Therapeutics NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Relmada Therapeutics Main Business Overview
13.2.5 Relmada Therapeutics Latest Developments
13.3 UCB
13.3.1 UCB Company Information
13.3.2 UCB NMDA Receptor Antagonist Product Offered
13.3.3 UCB NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 UCB Main Business Overview
13.3.5 UCB Latest Developments
13.4 Avanir Pharmaceuticals
13.4.1 Avanir Pharmaceuticals Company Information
13.4.2 Avanir Pharmaceuticals NMDA Receptor Antagonist Product Offered
13.4.3 Avanir Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Avanir Pharmaceuticals Main Business Overview
13.4.5 Avanir Pharmaceuticals Latest Developments
13.5 Axsome Therapeutics
13.5.1 Axsome Therapeutics Company Information
13.5.2 Axsome Therapeutics NMDA Receptor Antagonist Product Offered
13.5.3 Axsome Therapeutics NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Axsome Therapeutics Main Business Overview
13.5.5 Axsome Therapeutics Latest Developments
13.6 Seelos Therapeutics
13.6.1 Seelos Therapeutics Company Information
13.6.2 Seelos Therapeutics NMDA Receptor Antagonist Product Offered
13.6.3 Seelos Therapeutics NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Seelos Therapeutics Main Business Overview
13.6.5 Seelos Therapeutics Latest Developments
13.7 PharmaTher
13.7.1 PharmaTher Company Information
13.7.2 PharmaTher NMDA Receptor Antagonist Product Offered
13.7.3 PharmaTher NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 PharmaTher Main Business Overview
13.7.5 PharmaTher Latest Developments
13.8 Cessatech
13.8.1 Cessatech Company Information
13.8.2 Cessatech NMDA Receptor Antagonist Product Offered
13.8.3 Cessatech NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Cessatech Main Business Overview
13.8.5 Cessatech Latest Developments
13.9 ATAI Life Sciences
13.9.1 ATAI Life Sciences Company Information
13.9.2 ATAI Life Sciences NMDA Receptor Antagonist Product Offered
13.9.3 ATAI Life Sciences NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 ATAI Life Sciences Main Business Overview
13.9.5 ATAI Life Sciences Latest Developments
13.10 Small Pharma
13.10.1 Small Pharma Company Information
13.10.2 Small Pharma NMDA Receptor Antagonist Product Offered
13.10.3 Small Pharma NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Small Pharma Main Business Overview
13.10.5 Small Pharma Latest Developments
13.11 Bexson Biomedical
13.11.1 Bexson Biomedical Company Information
13.11.2 Bexson Biomedical NMDA Receptor Antagonist Product Offered
13.11.3 Bexson Biomedical NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Bexson Biomedical Main Business Overview
13.11.5 Bexson Biomedical Latest Developments
13.12 DemeRx
13.12.1 DemeRx Company Information
13.12.2 DemeRx NMDA Receptor Antagonist Product Offered
13.12.3 DemeRx NMDA Receptor Antagonist Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 DemeRx Main Business Overview
13.12.5 DemeRx Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. NMDA Receptor Antagonist Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. NMDA Receptor Antagonist Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Vaccine
Table 4. Major Players of Monoclonal Antibody
Table 5. Global NMDA Receptor Antagonist Sales by Type (2017-2022) & (K Units)
Table 6. Global NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
Table 7. Global NMDA Receptor Antagonist Revenue by Type (2017-2022) & ($ million)
Table 8. Global NMDA Receptor Antagonist Revenue Market Share by Type (2017-2022)
Table 9. Global NMDA Receptor Antagonist Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global NMDA Receptor Antagonist Sales by Application (2017-2022) & (K Units)
Table 11. Global NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Table 12. Global NMDA Receptor Antagonist Revenue by Application (2017-2022)
Table 13. Global NMDA Receptor Antagonist Revenue Market Share by Application (2017-2022)
Table 14. Global NMDA Receptor Antagonist Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global NMDA Receptor Antagonist Sales by Company (2020-2022) & (K Units)
Table 16. Global NMDA Receptor Antagonist Sales Market Share by Company (2020-2022)
Table 17. Global NMDA Receptor Antagonist Revenue by Company (2020-2022) ($ Millions)
Table 18. Global NMDA Receptor Antagonist Revenue Market Share by Company (2020-2022)
Table 19. Global NMDA Receptor Antagonist Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers NMDA Receptor Antagonist Producing Area Distribution and Sales Area
Table 21. Players NMDA Receptor Antagonist Products Offered
Table 22. NMDA Receptor Antagonist Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global NMDA Receptor Antagonist Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global NMDA Receptor Antagonist Sales Market Share Geographic Region (2017-2022)
Table 27. Global NMDA Receptor Antagonist Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global NMDA Receptor Antagonist Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global NMDA Receptor Antagonist Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global NMDA Receptor Antagonist Sales Market Share by Country/Region (2017-2022)
Table 31. Global NMDA Receptor Antagonist Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global NMDA Receptor Antagonist Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas NMDA Receptor Antagonist Sales by Country (2017-2022) & (K Units)
Table 34. Americas NMDA Receptor Antagonist Sales Market Share by Country (2017-2022)
Table 35. Americas NMDA Receptor Antagonist Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas NMDA Receptor Antagonist Revenue Market Share by Country (2017-2022)
Table 37. Americas NMDA Receptor Antagonist Sales by Type (2017-2022) & (K Units)
Table 38. Americas NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
Table 39. Americas NMDA Receptor Antagonist Sales by Application (2017-2022) & (K Units)
Table 40. Americas NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Table 41. APAC NMDA Receptor Antagonist Sales by Region (2017-2022) & (K Units)
Table 42. APAC NMDA Receptor Antagonist Sales Market Share by Region (2017-2022)
Table 43. APAC NMDA Receptor Antagonist Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC NMDA Receptor Antagonist Revenue Market Share by Region (2017-2022)
Table 45. APAC NMDA Receptor Antagonist Sales by Type (2017-2022) & (K Units)
Table 46. APAC NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
Table 47. APAC NMDA Receptor Antagonist Sales by Application (2017-2022) & (K Units)
Table 48. APAC NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Table 49. Europe NMDA Receptor Antagonist Sales by Country (2017-2022) & (K Units)
Table 50. Europe NMDA Receptor Antagonist Sales Market Share by Country (2017-2022)
Table 51. Europe NMDA Receptor Antagonist Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe NMDA Receptor Antagonist Revenue Market Share by Country (2017-2022)
Table 53. Europe NMDA Receptor Antagonist Sales by Type (2017-2022) & (K Units)
Table 54. Europe NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
Table 55. Europe NMDA Receptor Antagonist Sales by Application (2017-2022) & (K Units)
Table 56. Europe NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa NMDA Receptor Antagonist Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa NMDA Receptor Antagonist Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa NMDA Receptor Antagonist Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa NMDA Receptor Antagonist Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa NMDA Receptor Antagonist Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa NMDA Receptor Antagonist Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa NMDA Receptor Antagonist Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of NMDA Receptor Antagonist
Table 66. Key Market Challenges & Risks of NMDA Receptor Antagonist
Table 67. Key Industry Trends of NMDA Receptor Antagonist
Table 68. NMDA Receptor Antagonist Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. NMDA Receptor Antagonist Distributors List
Table 71. NMDA Receptor Antagonist Customer List
Table 72. Global NMDA Receptor Antagonist Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global NMDA Receptor Antagonist Sales Market Forecast by Region
Table 74. Global NMDA Receptor Antagonist Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global NMDA Receptor Antagonist Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas NMDA Receptor Antagonist Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas NMDA Receptor Antagonist Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC NMDA Receptor Antagonist Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC NMDA Receptor Antagonist Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe NMDA Receptor Antagonist Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe NMDA Receptor Antagonist Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa NMDA Receptor Antagonist Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa NMDA Receptor Antagonist Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global NMDA Receptor Antagonist Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global NMDA Receptor Antagonist Sales Market Share Forecast by Type (2023-2028)
Table 86. Global NMDA Receptor Antagonist Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global NMDA Receptor Antagonist Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global NMDA Receptor Antagonist Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global NMDA Receptor Antagonist Sales Market Share Forecast by Application (2023-2028)
Table 90. Global NMDA Receptor Antagonist Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global NMDA Receptor Antagonist Revenue Market Share Forecast by Application (2023-2028)
Table 92. Algernon Pharmaceuticals Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 93. Algernon Pharmaceuticals NMDA Receptor Antagonist Product Offered
Table 94. Algernon Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Algernon Pharmaceuticals Main Business
Table 96. Algernon Pharmaceuticals Latest Developments
Table 97. Relmada Therapeutics Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 98. Relmada Therapeutics NMDA Receptor Antagonist Product Offered
Table 99. Relmada Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Relmada Therapeutics Main Business
Table 101. Relmada Therapeutics Latest Developments
Table 102. UCB Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 103. UCB NMDA Receptor Antagonist Product Offered
Table 104. UCB NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. UCB Main Business
Table 106. UCB Latest Developments
Table 107. Avanir Pharmaceuticals Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 108. Avanir Pharmaceuticals NMDA Receptor Antagonist Product Offered
Table 109. Avanir Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Avanir Pharmaceuticals Main Business
Table 111. Avanir Pharmaceuticals Latest Developments
Table 112. Axsome Therapeutics Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 113. Axsome Therapeutics NMDA Receptor Antagonist Product Offered
Table 114. Axsome Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Axsome Therapeutics Main Business
Table 116. Axsome Therapeutics Latest Developments
Table 117. Seelos Therapeutics Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 118. Seelos Therapeutics NMDA Receptor Antagonist Product Offered
Table 119. Seelos Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Seelos Therapeutics Main Business
Table 121. Seelos Therapeutics Latest Developments
Table 122. PharmaTher Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 123. PharmaTher NMDA Receptor Antagonist Product Offered
Table 124. PharmaTher NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. PharmaTher Main Business
Table 126. PharmaTher Latest Developments
Table 127. Cessatech Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 128. Cessatech NMDA Receptor Antagonist Product Offered
Table 129. Cessatech NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Cessatech Main Business
Table 131. Cessatech Latest Developments
Table 132. ATAI Life Sciences Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 133. ATAI Life Sciences NMDA Receptor Antagonist Product Offered
Table 134. ATAI Life Sciences NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. ATAI Life Sciences Main Business
Table 136. ATAI Life Sciences Latest Developments
Table 137. Small Pharma Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 138. Small Pharma NMDA Receptor Antagonist Product Offered
Table 139. Small Pharma NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Small Pharma Main Business
Table 141. Small Pharma Latest Developments
Table 142. Bexson Biomedical Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 143. Bexson Biomedical NMDA Receptor Antagonist Product Offered
Table 144. Bexson Biomedical NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Bexson Biomedical Main Business
Table 146. Bexson Biomedical Latest Developments
Table 147. DemeRx Basic Information, NMDA Receptor Antagonist Manufacturing Base, Sales Area and Its Competitors
Table 148. DemeRx NMDA Receptor Antagonist Product Offered
Table 149. DemeRx NMDA Receptor Antagonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. DemeRx Main Business
Table 151. DemeRx Latest Developments
List of Figures
Figure 1. Picture of NMDA Receptor Antagonist
Figure 2. NMDA Receptor Antagonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NMDA Receptor Antagonist Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global NMDA Receptor Antagonist Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. NMDA Receptor Antagonist Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Vaccine
Figure 10. Product Picture of Monoclonal Antibody
Figure 11. Global NMDA Receptor Antagonist Sales Market Share by Type in 2021
Figure 12. Global NMDA Receptor Antagonist Revenue Market Share by Type (2017-2022)
Figure 13. NMDA Receptor Antagonist Consumed in Parkinson's Disease
Figure 14. Global NMDA Receptor Antagonist Market: Parkinson's Disease (2017-2022) & (K Units)
Figure 15. NMDA Receptor Antagonist Consumed in Alzheimer's Disease
Figure 16. Global NMDA Receptor Antagonist Market: Alzheimer's Disease (2017-2022) & (K Units)
Figure 17. NMDA Receptor Antagonist Consumed in Others
Figure 18. Global NMDA Receptor Antagonist Market: Others (2017-2022) & (K Units)
Figure 19. Global NMDA Receptor Antagonist Sales Market Share by Application (2017-2022)
Figure 20. Global NMDA Receptor Antagonist Revenue Market Share by Application in 2021
Figure 21. NMDA Receptor Antagonist Revenue Market by Company in 2021 ($ Million)
Figure 22. Global NMDA Receptor Antagonist Revenue Market Share by Company in 2021
Figure 23. Global NMDA Receptor Antagonist Sales Market Share by Geographic Region (2017-2022)
Figure 24. Global NMDA Receptor Antagonist Revenue Market Share by Geographic Region in 2021
Figure 25. Global NMDA Receptor Antagonist Sales Market Share by Region (2017-2022)
Figure 26. Global NMDA Receptor Antagonist Revenue Market Share by Country/Region in 2021
Figure 27. Americas NMDA Receptor Antagonist Sales 2017-2022 (K Units)
Figure 28. Americas NMDA Receptor Antagonist Revenue 2017-2022 ($ Millions)
Figure 29. APAC NMDA Receptor Antagonist Sales 2017-2022 (K Units)
Figure 30. APAC NMDA Receptor Antagonist Revenue 2017-2022 ($ Millions)
Figure 31. Europe NMDA Receptor Antagonist Sales 2017-2022 (K Units)
Figure 32. Europe NMDA Receptor Antagonist Revenue 2017-2022 ($ Millions)
Figure 33. Middle East & Africa NMDA Receptor Antagonist Sales 2017-2022 (K Units)
Figure 34. Middle East & Africa NMDA Receptor Antagonist Revenue 2017-2022 ($ Millions)
Figure 35. Americas NMDA Receptor Antagonist Sales Market Share by Country in 2021
Figure 36. Americas NMDA Receptor Antagonist Revenue Market Share by Country in 2021
Figure 37. United States NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 38. Canada NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 39. Mexico NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 40. Brazil NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 41. APAC NMDA Receptor Antagonist Sales Market Share by Region in 2021
Figure 42. APAC NMDA Receptor Antagonist Revenue Market Share by Regions in 2021
Figure 43. China NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 44. Japan NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 45. South Korea NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 46. Southeast Asia NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 47. India NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 48. Australia NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 49. Europe NMDA Receptor Antagonist Sales Market Share by Country in 2021
Figure 50. Europe NMDA Receptor Antagonist Revenue Market Share by Country in 2021
Figure 51. Germany NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 52. France NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 53. UK NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 54. Italy NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 55. Russia NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 56. Middle East & Africa NMDA Receptor Antagonist Sales Market Share by Country in 2021
Figure 57. Middle East & Africa NMDA Receptor Antagonist Revenue Market Share by Country in 2021
Figure 58. Egypt NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 59. South Africa NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 60. Israel NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 61. Turkey NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 62. GCC Country NMDA Receptor Antagonist Revenue Growth 2017-2022 ($ Millions)
Figure 63. Manufacturing Cost Structure Analysis of NMDA Receptor Antagonist in 2021
Figure 64. Manufacturing Process Analysis of NMDA Receptor Antagonist
Figure 65. Industry Chain Structure of NMDA Receptor Antagonist
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets